Literature DB >> 6199125

Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2.

V J Merluzzi, D M Savage, R Mertelsmann, K Welte.   

Abstract

Murine spleen cells developed into nonspecific cytotoxic cells within 72 hr of culture in the presence of highly purified sources of human interleukin 2. In whole spleen cell cultures, human interleukin 2 generated effector cells which were Thy 1.2+, Lyt 2.2+, resistant to gamma irradiation (1000 R), and capable of lysing both H-2 compatible and incompatible targets. The effector cells generated in this manner were not restricted to classical natural killer cell-sensitive targets. If thymus-derived cells (T cells) were depleted from the spleen cell population before culture with human interleukin 2, the effector cells generated were enriched in effectors capable of lysing natural killer cell-sensitive targets. Interferon was not produced in interleukin 2-stimulated spleen cell cultures. In addition, heterologous antibody to murine gamma-interferon did not abrogate the generation of cytotoxic cells by human interleukin 2. These and additional data suggest that human interleukin 2 is capable of stimulating gamma-irradiation-sensitive Thy 1.2+ cell(s) capable of lysing a variety of target cells regardless of inherent sensitivities to classical natural killer cells. Thy 1.2- cells were also stimulated by human interleukin 2 and lysed only natural killer cell-sensitive targets. Human interleukin 2 caused some Thy 1.2- cells to become susceptible to lysis by anti-Thy 1.2 serum and complement.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199125     DOI: 10.1016/0008-8749(84)90078-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  18 in total

1.  Photoaffinity labeling of ATP and NAD+ binding sites on recombinant human interleukin 2.

Authors:  S Campbell; H Kim; M Doukas; B Haley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta.

Authors:  K D Boehm; M F Kelley; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.

Authors:  K Shiiba; R Suzuki; K Kawakami; A Ohuchi; K Kumagai
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations.

Authors:  R Agah; H Shau; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Lysis of primary hepatic tumours by lymphokine activated killer cells.

Authors:  K H Hsieh; S Y Shu; C S Lee; C T Chu; C S Yang; K J Chang
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

6.  Association of reduced interleukin-2 production with genetic susceptibility to Pichinde virus in inbred strains of hamsters.

Authors:  K E Wright; K L Rosenthal; W E Rawls
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

7.  A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Authors:  P B Chapman; J E Kolitz; T B Hakes; J L Gabrilove; K Welte; V J Merluzzi; A Engert; E C Bradley; M Konrad; R Mertelsmann
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

8.  T-suppressor clones derived from murine AMLR.

Authors:  M H Bocchieri
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

9.  Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.

Authors:  S Hinuma; K Naruo; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

10.  Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.

Authors:  R R Salup; R H Wiltrout
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.